Consistent with preclinical findings, this strategy has already proven effective in the clinic, evident by increased patient response rates when CD47 blockade is combined with the anti-CD20 antibody, rituximab, or the anti-HER2 antibody, trastuzumab, in patients with lymphoma or advanced solid cancers, respectively [254,256,274]. This evidence concerns the gene CD47 and lymphoma.